drugset / Trial / NCT04780217
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors
Timeline
- Start
- 2021-08-10
- Primary completion
- 2025-03
- Completion
- 2025-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | T3011 | Other / unclassified | — | Intravenous |